Longitudinal Analyses of Antibody Responses to SARS-CoV-2

SARS-CoV-2 抗体反应的纵向分析

• 批准号: 10688391
• 负责人: JAMES E Robinson
• 金额: $ 51.01万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-30 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10688391
• 关键词: 2019-nCoV; Address; Antibodies; Antibody Response; Antibody-mediated protection; Area; Biological Assay; COVID-19; Clinical; Communities; Country; Data; Data Set; Development; Disease; Epidemic; Evolution; Exposure to; Follow-Up Studies; Future; Human; Humoral Immunities; Immune; Immune response; Immunity; Immunoassay; Immunocompetent; Immunologic Deficiency Syndromes; Immunologic Memory; Individual; Infection; Knowledge; Longitudinal Studies; Longterm Follow-up; Malignant Neoplasms; Measurement; Measures; Methodology; Patients; Persons; Population; SARS coronavirus; SARS-CoV-2 antibody; SARS-CoV-2 immunity; SARS-CoV-2 infection; Serology; Serology test; Seroprevalences; Shapes; Standardization; T-Lymphocyte; Testing; Time; Universities; Virus; antibody test; cohort; coronavirus disease; human subject; immune function; insight; longitudinal analysis; novel; pandemic disease; response; seasonal coronavirus; tool

Project 1 Summary We will conduct comprehensive studies of immune responses in human subjects who have current or past infections with SARS-CoV-2. An overarching aim is to understand whether immune responses to CoV-2 infections confer protection against future repeat episodes of COVID19 and whether CoV-2 immunity is long lasting. We propose the hypothesis that once immunocompetent human beings have had any form of COVID19, they will never get the full disease again. On the other hand, long term follow-up studies of CoV-2 immunity in patients with cancer or any cause of immunodeficiency will include plans to look for reinfection and repeat episodes of COVID19. There is a clear need for accurate serologic assays to determine who in a given community has had infection with SARS CoV-2. Many assays marketed early in the pandemic are prone to false positive and negative results. We plan to validate our efficient and sensitive immunoassays for routine serodiagnosis of SARS CoV-2 infections. It should be admitted that even the best assay is going miss unusual cases where a person tested positive by PCR but shows up negative in antibody tests. Although the antibody assay could be falsely negative, it is also possible that the person was truly infected by did not develop humoral immunity. In project 2, we will test the possibility that measuring T cell immunity may confirm that even some antibody negative patients have immunity to the virus after all.

项目1摘要 我们将对具有当前或过去的人类受试者的免疫反应进行全面研究 SARS-COV-2感染。总体目的是了解是否免疫反应COV-2 感染允许对COVID19的未来重复发作的保护以及COV-2免疫是否长 持久。我们提出这样的假设，即一旦免疫能力的人类有任何形式 Covid19，他们将永远不会再患上全部疾病。另一方面，COV-2的长期随访研究 癌症患者或任何免疫缺陷病因的免疫力将包括寻找重新感染和 COVID19的重复发作。显然需要准确的血清学测定，以确定给定的谁 社区已经感染了SARS COV-2。大流行的早期销售的许多测定很容易 假阳性和负面结果。我们计划验证我们的有效和敏感的免疫测定法规 SARS COV-2感染的血清诊断。应该承认，即使是最好的测定法 一个人以PCR测试呈阳性但在抗体测试中显示阴性的情况。虽然抗体 测定可能是虚假的，也有可能真正被人感染 体液免疫。在项目2中，我们将测试测量T细胞免疫力可能证实的可能性 甚至一些抗体阴性患者毕竟对病毒也有免疫力。